×
About 375 results

ALLMedicine™ Papillary Tumors Center

Research & Reviews  177 results

Papillary tumor of the pineal region in pediatric populations: An additional case and s...
https://doi.org/10.1016/j.clineuro.2020.106404
Clinical Neurology and Neurosurgery; Mathkour M, Hanna J et. al.

Dec 28th, 2020 - Papillary tumors of the pineal region (PTPR) are a rare tumor entity first described in 2003, later codified in the 2007 WHO tumor classification system. PTPRs most commonly occur in the third and fourth decades, with exceedingly rare presentation...

Endoscopic pancreaticobiliary drainage with overlength stents to prevent delayed perfor...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7701946
World Journal of Gastroenterology; Wu L, Liu F et. al.

Dec 14th, 2020 - Endoscopic papillectomy (EP) is rapidly replacing traditional surgical resection and is a less invasive procedure for the treatment of duodenal papillary tumors in selected patients. With the expansion of indications, concerns regarding EP include...

Cannulation procedure optimization for patients with duodenal papillary tumors.
https://doi.org/10.1007/s00464-020-08076-4
Surgical Endoscopy; Hong J, Zhu H et. al.

Oct 10th, 2020 - The goal of this study was to compare the efficacy and safety of needle-knife fistulotomy (NKF) to that of conventional cannulation methods (CCMs) when used for primary biliary access in patients with duodenal papillary tumors. Consecutive patient...

Adenomatoid Tumor: A Review of Pathology With Focus on Unusual Presentations and Sites,...
https://doi.org/10.1097/PAP.0000000000000278
Advances in Anatomic Pathology; Karpathiou G, Hiroshima K et. al.

Aug 9th, 2020 - Adenomatoid tumors have been described almost a century ago, and their nature has been the subject of debate for decades. They are tumors of mesothelial origin usually involving the uterus, the Fallopian tubes, and the paratesticular region. Adeno...

FDA Approves Pembrolizumab for BCG-Unresponsive NMIBC.
https://www.ncbi.nlm.nih.gov/pubmed/32645193
Oncology (Williston Park, N.Y.); Wright KM

Jul 9th, 2020 - The FDA approved pembrolizumab (Keytruda) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are i...

see more →

Guidelines  1 results

FDA approves pembrolizumab for BCG-unresponsive, high-risk non-muscle invasive bladder cancer
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer

Jan 7th, 2020 - The Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck & Co. Inc.) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS)...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  191 results

Papillary tumor of the pineal region in pediatric populations: An additional case and s...
https://doi.org/10.1016/j.clineuro.2020.106404
Clinical Neurology and Neurosurgery; Mathkour M, Hanna J et. al.

Dec 28th, 2020 - Papillary tumors of the pineal region (PTPR) are a rare tumor entity first described in 2003, later codified in the 2007 WHO tumor classification system. PTPRs most commonly occur in the third and fourth decades, with exceedingly rare presentation...

Endoscopic pancreaticobiliary drainage with overlength stents to prevent delayed perfor...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7701946
World Journal of Gastroenterology; Wu L, Liu F et. al.

Dec 14th, 2020 - Endoscopic papillectomy (EP) is rapidly replacing traditional surgical resection and is a less invasive procedure for the treatment of duodenal papillary tumors in selected patients. With the expansion of indications, concerns regarding EP include...

Cannulation procedure optimization for patients with duodenal papillary tumors.
https://doi.org/10.1007/s00464-020-08076-4
Surgical Endoscopy; Hong J, Zhu H et. al.

Oct 10th, 2020 - The goal of this study was to compare the efficacy and safety of needle-knife fistulotomy (NKF) to that of conventional cannulation methods (CCMs) when used for primary biliary access in patients with duodenal papillary tumors. Consecutive patient...

Novel Indications and New Drugs for the Treatment of Bladder Cancer
https://ascopost.com/issues/august-25-2020-supplement-genitourinary-cancers-almanac/novel-indications-and-new-drugs-for-the-treatment-of-bladder-cancer/

Aug 24th, 2020 - Pembrolizumab: On January 8, 2020, pembrolizumab (Keytruda) was approved by the U.S. Food and Drug Administration (FDA) for Bacillus Calmette-Guérin (BCG)-unresponsive, high-risk, non–muscle invasive bladder cancer with carcinoma in situ with or w...

Fast Five Quiz: Urothelial Carcinoma
https://reference.medscape.com/viewarticle/935309_2

Aug 12th, 2020 - Figure 1. Bladder cancer. Illustration of sagittal section of the female pelvis showing cancer in the muscular wall of the bladder. Additional anatomy shown includes the uterus, vagina, and portions of the rectum and small intestine. Low-grade pro...

see more →

News  5 results

Fast Five Quiz: Urothelial Carcinoma
https://reference.medscape.com/viewarticle/935309_2

Aug 12th, 2020 - Figure 1. Bladder cancer. Illustration of sagittal section of the female pelvis showing cancer in the muscular wall of the bladder. Additional anatomy shown includes the uterus, vagina, and portions of the rectum and small intestine. Low-grade pro...

FDA approves pembrolizumab for BCG-unresponsive NMIBC with CIS
https://www.mdedge.com/hematology-oncology/article/215228/genitourinary-cancer/fda-approves-pembrolizumab-bcg-unresponsive?channel=39313
Laura Nikolaides

Jan 8th, 2020 - The Food and Drug Administration has approved pembrolizumab (Keytruda) for the treatment of patients with Bacillus Calmette-Guérin (BCG)–unresponsive, high-risk, non–muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or with.

FDA approves pembrolizumab for BCG-unresponsive, high-risk non-muscle invasive bladder cancer
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer

Jan 7th, 2020 - The Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck & Co. Inc.) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS)...

Expanding the Scope of Cystoscopy: Imaging Agent Illuminates More Lesions
https://www.onclive.com/publications/oncology-live/2011/september-2011/expanding-the-scope-of-cystoscopy-imaging-agent-illuminates-more-lesions

Oct 10th, 2011 - Neal D. Shore, MD Although cystoscopy is a mainstay in diagnosing bladder cancer and monitoring its recurrence, researchers have been seeking to improve upon its ability to detect early evidence of cancer, particularly flat lesions and small papil...

Role of Immunotherapy in Renal Cell Carcinoma
https://www.medscape.com/viewarticle/408449

Abstract and Introduction Renal cell carcinoma develops in over 30,000 individuals annually in the United States, with 12,000 deaths attributed to this tumor on a yearly basis. The etiology of this neoplasm is unknown, but cigarette use appears to...

see more →